“…In this study, these benefits are due to significant and sustained improvements in patients who were enrolled in an ART programme, with regard to the fatigue they suffered, their ability to perform normal tasks, increased rates of employment, and reductions in difficulties with job performance experienced by those in work (Rosen et al., ), reflecting both increasing workforce participation and, crucially, improved productivity at work. As a result, there is an increasing emphasis on more precisely quantifying the economic benefits of workplace programmes, accounting for the significant impact on productivity observed in HIV positive workers who have access to treatment and thus going beyond the standard framework which concentrates on costs “avoided,” documenting the challenges and barriers to the uptake and success of workplace programmes, as well as identifying best practice to support expanded implementation across the private sector (AIDS Accountability International & Rosencrantz and Co, ; George, ; ILO, ; Scott et al., ; UNAIDS, ). With ARVs increasingly (though in some cases intermittently) provided free at the point of access in many sub‐Saharan countries, the business case may be further enhanced if costs of treatment are removed from estimates of the costs of workplace programmes.…”